

- Fisher B, Costantino JP, Wickerham DL, et al. Tamoxifen for the prevention of breast cancer: current status of the National Surgical Adjuvant Breast and Bowel Project P-1 study. *J Natl Cancer Inst* 2005;97:1652–1662.
- Fisher B, Dignam J, Wolmark N, et al. Tamoxifen in treatment of intraductal breast cancer: National Surgical Adjuvant Breast and Bowel Project B-24 randomised controlled trial. *Lancet* 1999;353:1993–2000.
- Colleoni M, Gelber S, Goldhirsch A, et al. Tamoxifen after adjuvant chemotherapy for premenopausal women with lymph node-positive breast cancer: International Breast Cancer Study Group Trial 13-93. *J Clin Oncol* 2006;24:1332–1341.
- Davies C, Pan H, Godwin J, et al. Long-term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years after diagnosis of oestrogen receptor-positive breast cancer: ATLAS, a randomised trial. *Lancet* 2013;381:805–816.
- Loprinzi CL, Michalak JC, Quella SK, et al. Megestrol acetate for the prevention of hot flashes. *N Engl J Med* 1994;331:347–352.
- Loprinzi CL, Kugler JW, Sloan JA, et al. Venlafaxine in management of hot flashes in survivors of breast cancer: a randomised controlled trial. *Lancet* 2000;356:2059–2063.
- Archer DF, Dupont CM, Constantine GD, et al. Desvenlafaxine for the treatment of vasomotor symptoms associated with menopause: a double-blind, randomized, placebo-controlled trial of efficacy and safety. *Am J Obstet Gynecol* 2009;200:238.e1–238.e10.
- Barton DL, LaVasseur BI, Sloan JA, et al. Phase III, placebo-controlled trial of three doses of citalopram for the treatment of hot flashes: NCCTG trial N05C9. *J Clin Oncol* 2010;28:3278–3283.
- Freeman EW, Guthrie KA, Caan B, et al. Efficacy of escitalopram for hot flashes in healthy menopausal women: a randomized controlled trial. *JAMA* 2011;305:267–274.
- Stearns V, Beebe KL, Iyengar M, et al. Paroxetine controlled release in the treatment of menopausal hot flashes: a randomized controlled trial. *JAMA* 2003;289:2827–2834.
- Pandya KJ, Morrow GR, Roscoe JA, et al. Gabapentin for hot flashes in 420 women with breast cancer: a randomised double-blind placebo-controlled trial. *Lancet* 2005;366:818–824.
- Loprinzi CL, Qin R, Balceva EP, et al. Phase III, randomized, double-blind, placebo-controlled evaluation of pregabalin for alleviating hot flashes, N07C1. *J Clin Oncol* 2010;28:641–647.
- Madlensky L, Natarajan L, Tchu S, et al. Tamoxifen metabolite concentrations, CYP2D6 genotype, and breast cancer outcomes. *Clin Pharmacol Ther* 2011;89:718–725.
- Tamoxifen for early breast cancer: an overview of the randomised trials. Early Breast Cancer Trialists' Collaborative Group. *Lancet* 1998;351:1451–1467.
- Wickerham DL, Fisher B, Wolmark N, et al. Association of tamoxifen and uterine sarcoma. *J Clin Oncol* 2002;20:2758–2760.
- Dewar JA, Horobin JM, Preece PE, et al. Long term effects of tamoxifen on blood lipid values in breast cancer. *BMJ* 1992;305:225–226.
- Love RR, Mazess RB, Barden HS, et al. Effects of tamoxifen on bone mineral density in postmenopausal women with breast cancer. *N Engl J Med* 1992;326:852–856.
- Powles TJ, Hickish T, Kanis JA, et al. Effect of tamoxifen on bone mineral density measured by dual-energy x-ray absorptiometry in healthy premenopausal and postmenopausal women. *J Clin Oncol* 1996;14:78–84.
- Buzdar A, Howell A, Cuzick J, et al. Comprehensive side-effect profile of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: long-term safety analysis of the ATAC trial. *Lancet Oncol* 2006;7:633–643.
- Gorin MB, Day R, Costantino JP, et al. Long-term tamoxifen citrate use and potential ocular toxicity. *Am J Ophthalmol* 1998;125:493–501.
- Tonetti DA, Jordan VC. Possible mechanisms in the emergence of tamoxifen-resistant breast cancer. *Anticancer Drugs* 1995;6:498–507.
- Lim YC, Desta Z, Flockhart DA, et al. Endoxifen (4-hydroxy-N-desmethyl-tamoxifen) has anti-estrogenic effects in breast cancer cells with potency similar to 4-hydroxy-tamoxifen. *Cancer Chemother Pharmacol* 2005;55:471–478.
- Benz CC, Scott GK, Sarup JC, et al. Estrogen-dependent, tamoxifen-resistant tumorigenic growth of MCF-7 cells transfected with HER2/neu. *Breast Cancer Res Treat* 1993;24:85–95.
- Borg A, Baldeorj B, Ferno M, et al. ERBB2 amplification is associated with tamoxifen resistance in steroid-receptor positive breast cancer. *Cancer Lett* 1994;81:137–144.
- Houston SJ, Plunkett TA, Barnes DM, et al. Overexpression of c-erbB2 is an independent marker of resistance to endocrine therapy in advanced breast cancer. *Br J Cancer* 1999;79:1220–1226.
- Lipton A, Ali SM, Leitzel K, et al. Serum HER-2/neu and response to the aromatase inhibitor letrozole versus tamoxifen. *J Clin Oncol* 2003;21:1967–1972.
- Bunone G, Briand PA, Miksicek RJ, et al. Activation of the unliganded estrogen receptor by EGF involves the MAP kinase pathway and direct phosphorylation. *Embo J* 1996;15:2174–2183.
- Kato S, Endoh H, Masuhiro Y, et al. Activation of the estrogen receptor through phosphorylation by mitogen-activated protein kinase. *Science* 1995;270:1491–1494.
- Pietras RJ, Arboleda J, Reese DM, et al. HER-2 tyrosine kinase pathway targets estrogen receptor and promotes hormone-independent growth in human breast cancer cells. *Oncogene* 1995;10:2435–2446.
- Osborne CK, Bardou V, Hopp TA, et al. Role of the estrogen receptor coactivator AIB1 (SRC-3) and HER-2/neu in tamoxifen resistance in breast cancer. *J Natl Cancer Inst* 2003;95:353–361.
- Encarnacion CA, Ciocca DR, McGuire WL, et al. Measurement of steroid hormone receptors in breast cancer patients on tamoxifen. *Breast Cancer Res Treat* 1993;26:237–246.
- Watts CK, Handel ML, King RJ, et al. Oestrogen receptor gene structure and function in breast cancer. *J Steroid Biochem Mol Biol* 1992;41:529–536.
- Zhang QX, Borg A, Wolf DM, et al. An estrogen receptor mutant with strong hormone-independent activity from a metastatic breast cancer. *Cancer Res* 1997;57:1244–1249.
- Toy W, Shen Y, Won H, et al. ESR1 ligand-binding domain mutations in hormone-resistant breast cancer. *Nat Genet* 2013;45:1439–1445.
- Robinson DR, Wu YM, Vats P, et al. Activating ESR1 mutations in hormone-resistant metastatic breast cancer. *Nat Genet* 2013;45:1446–1451.
- Merenbakh-Lamin K, Ben-Baruch N, Yeheskel A, et al. D538G mutation in estrogen receptor- $\alpha$ : a novel mechanism for acquired endocrine resistance in breast cancer. *Cancer Res* 2013;73:6856–6864.
- Fendl KC, Zimmiski SJ. Role of tamoxifen in the induction of hormone-independent rat mammary tumors. *Cancer Res* 1992;52:235–237.
- Williams GM. Tamoxifen experimental carcinogenicity studies: implications for human effects. *Proc Soc Exp Biol Med* 1995;208:141–143.
- Williams GM, Iatropoulos MJ, Djordjevic MV, et al. The triphenylethylene drug tamoxifen is a strong liver carcinogen in the rat. *Carcinogenesis* 1993;14:315–317.
- Rutqvist LE, Johansson H, Signomkiao T, et al. Adjuvant tamoxifen therapy for early stage breast cancer and second primary malignancies. Stockholm Breast Cancer Study Group. *J Natl Cancer Inst* 1995;87:645–651.
- Mani C, Kupfer D. Cytochrome P-450-mediated activation and irreversible binding of the antiestrogen tamoxifen to proteins in rat and human liver: possible involvement of flavin-containing monooxygenases in tamoxifen activation. *Cancer Res* 1991;51:6052–6058.
- Mani C, Pearce R, Parkinson A, et al. Involvement of cytochrome P4503A in catalysis of tamoxifen activation and covalent binding to rat and human liver microsomes. *Carcinogenesis* 1994;15:2715–2720.
- Styles JA, Davies A, Lim CK, et al. Genotoxicity of tamoxifen, tamoxifen epoxide and toremifene in human lymphoblastoid cells containing human cytochrome P450s. *Carcinogenesis* 1994;15:5–9.
- Han XL, Liehr JG. Induction of covalent DNA adducts in rodents by tamoxifen. *Cancer Res* 1992;52:1360–1363.
- Mani C, Hodgson E, Kupfer D. Metabolism of the antimammary cancer antiestrogenic agent tamoxifen. II. Flavin-containing monooxygenase-mediated N-oxidation. *Drug Metab Dispos* 1993;21:657–661.
- Mani C, Gelboin HV, Park SS, et al. Metabolism of the antimammary cancer antiestrogenic agent tamoxifen. I. Cytochrome P-450-catalyzed N-demethylation and 4-hydroxylation. *Drug Metab Dispos* 1993;21:645–656.
- Albain KS, Barlow WE, Shak S, et al. Prognostic and predictive value of the 21-gene recurrence score assay in postmenopausal women with node-positive, oestrogen-receptor-positive breast cancer on chemotherapy: a retrospective analysis of a randomised trial. *Lancet Oncol* 2010;11:55–65.
- Dowsett M, Cuzick J, Wale C, et al. Prediction of risk of distant recurrence using the 21-gene recurrence score in node-negative and node-positive postmenopausal patients with breast cancer treated with anastrozole or tamoxifen: a TransATAC study. *J Clin Oncol* 2010;28:1829–1834.
- Paik S, Shak S, Tang G, et al. A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. *N Engl J Med* 2004;351:2817–2826.
- Johnson MD, Zuo H, Lee KH, et al. Pharmacological characterization of 4-hydroxy-N-desmethyl tamoxifen, a novel active metabolite of tamoxifen. *Breast Cancer Res Treat* 2004;85:151–159.
- Lim YC, Li L, Desta Z, et al. Endoxifen, a secondary metabolite of tamoxifen, and 4-OH-tamoxifen induce similar changes in global gene expression patterns in MCF-7 breast cancer cells. *J Pharmacol Exp Ther* 2006;318:503–512.
- Wu X, Hawse JR, Subramaniam M, et al. The tamoxifen metabolite, endoxifen, is a potent antiestrogen that targets estrogen receptor  $\alpha$  for degradation in breast cancer cells. *Cancer Res* 2009;69:1722–1727.
- Jin Y, Desta Z, Stearns V, et al. CYP2D6 genotype, antidepressant use, and tamoxifen metabolism during adjuvant breast cancer treatment. *J Natl Cancer Inst* 2005;97:30–39.
- Desta Z, Ward BA, Soukhova NV, et al. Comprehensive evaluation of tamoxifen sequential biotransformation by the human cytochrome P450 system in vitro: prominent roles for CYP3A and CYP2D6. *J Pharmacol Exp Ther* 2004;310:1062–1075.
- Stearns V, Johnson MD, Rae JM, et al. Active tamoxifen metabolite plasma concentrations after coadministration of tamoxifen and the selective serotonin reuptake inhibitor paroxetine. *J Natl Cancer Inst* 2003;95:1758–1764.
- Goetz MP, Rae JM, Suman VJ, et al. Pharmacogenetics of tamoxifen biotransformation is associated with clinical outcomes of efficacy and hot flashes. *J Clin Oncol* 2005;23:9312–9318.

57. Schroth W, Antoniadou L, Fritz P, et al. Breast cancer treatment outcome with adjuvant tamoxifen relative to patient CYP2D6 and CYP2C19 genotypes. *J Clin Oncol* 2007;25:5187–5193.
58. Schroth W, Goetz MP, Hamann U, et al. Association between CYP2D6 polymorphisms and outcomes among women with early stage breast cancer treated with tamoxifen. *JAMA* 2009;302:1429–1436.
59. Rae JM, Drury S, Hayes DF, et al. CYP2D6 and UGT2B7 genotype and risk of recurrence in tamoxifen-treated breast cancer patients. *J Natl Cancer Inst* 2012;104:452–460.
60. Regan MM, Leyland-Jones B, Bouzyk M, et al. CYP2D6 genotype and tamoxifen response in postmenopausal women with endocrine-responsive breast cancer: the breast international group 1-98 trial. *J Natl Cancer Inst* 2012;104:441–451.
61. Goetz MP, Suman VJ, Hoskin TL, et al. CYP2D6 metabolism and patient outcome in the Austrian Breast and Colorectal Cancer Study Group trial (ABCSC) 8. *Clin Cancer Res* 2013;19:500–507.
62. Province MA, Goetz MP, Brauch H, et al. CYP2D6 Genotype and adjuvant tamoxifen: meta-analysis of heterogeneous study populations. *Clin Pharmacol Ther* 2014;95:216–227.
63. Borges S, Desta Z, Li L, et al. Quantitative effect of CYP2D6 genotype and inhibitors on tamoxifen metabolism: implication for optimization of breast cancer treatment. *Clin Pharmacol Ther* 2006;80:61–74.
64. Dezentje VO, van Blijderveen NJ, Gelderblom H, et al. Effect of concomitant CYP2D6 inhibitor use and tamoxifen adherence on breast cancer recurrence in early-stage breast cancer. *J Clin Oncol* 2010;28:2423–2429.
65. Kelly CM, Juurlink DN, Gomes T, et al. Selective serotonin reuptake inhibitors and breast cancer mortality in women receiving tamoxifen: a population based cohort study. *BMJ* 2010;340:c693.
66. Binkhorst L, van Gelder T, Loos WJ, et al. Effects of CYP induction by rifampicin on tamoxifen exposure. *Clin Pharmacol Ther* 2012;92:62–67.
67. Irvin WJ Jr, Walko CM, Weck KE, et al. Genotype-guided tamoxifen dosing increases active metabolite exposure in women with reduced CYP2D6 metabolism: a multicenter study. *J Clin Oncol* 2011;29:3232–3239.
68. Kiyotani K, Mushiroya T, Imamura CK, et al. Dose-adjustment study of tamoxifen based on CYP2D6 genotypes in Japanese breast cancer patients. *Breast Cancer Res Treat* 2012;131:137–145.
69. Goetz MP, Suman VA, Reid JR, et al. A first-in-human phase I study of the tamoxifen (TAM) metabolite, Z-endoxifen hydrochloride (Z-Endx) in women with aromatase inhibitor (AI) refractory metastatic breast cancer (MBC) (NCT01327781). *Cancer Res* 2013;73(24 Suppl): Abstract nr PD3-4.
70. Lien EA, Anker G, Lonning PE, et al. Decreased serum concentrations of tamoxifen and its metabolites induced by aminoglutethimide. *Cancer Res* 1990;50:5851–5857.
71. Adam HK, Patterson JS, Kemp JV. Studies on the metabolism and pharmacokinetics of tamoxifen in normal volunteers. *Cancer Treat Rep* 1980;64:761–764.
72. Patterson JS, Settattree RS, Adam HK, et al. Serum concentrations of tamoxifen and major metabolite during long-term nolvadex therapy, correlated with clinical response. *Eur J Cancer Suppl* 1980;1:89–92.
73. Camaggi CM, Strocchi E, Canova N, et al. Medroxyprogesterone acetate (MAP) and tamoxifen (TMX) plasma levels after simultaneous treatment with 'low' TMX and 'high' MAP doses. *Cancer Chemother Pharmacol* 1985;14:229–231.
74. Lien EA, Solheim E, Lea OA, et al. Distribution of 4-hydroxy-N-desmethyl-tamoxifen and other tamoxifen metabolites in human biological fluids during tamoxifen treatment. *Cancer Res* 1989;49:2175–2183.
75. Lien EA, Solheim E, Ueland PM. Distribution of tamoxifen and its metabolites in rat and human tissues during steady-state treatment. *Cancer Res* 1991;51:4837–4844.
76. Daniel P, Gaskell SJ, Bishop H, et al. Determination of tamoxifen and biologically active metabolites in human breast tumours and plasma. *Eur J Cancer Clin Oncol* 1981;17:1183–1189.
77. Robinson SP, Langan-Fahey SM, Johnson DA, et al. Metabolites, pharmacodynamics, and pharmacokinetics of tamoxifen in rats and mice compared to the breast cancer patient. *Drug Metab Dispos* 1991;19:36–43.
78. DeGregorio MW, Wiebe VJ, Venook AP, et al. Elevated plasma tamoxifen levels in a patient with liver obstruction. *Cancer Chemother Pharmacol* 1989;23:194–195.
79. Lodwick R, McConkey B, Brown AM. Life threatening interaction between tamoxifen and warfarin. *Br Med J (Clin Res Ed)* 1987;295:1141.
80. Ritchie LD, Grant SM. Tamoxifen-warfarin interaction: the Aberdeen hospitals drug file. *BMJ* 1989;298:1253.
81. Tenni P, Lalich DL, Byrne MJ. Life threatening interaction between tamoxifen and warfarin. *BMJ* 1989;298:93.
82. Rabinowicz AL, Hinton DR, Dyck P, et al. High-dose tamoxifen in treatment of brain tumors: interaction with antiepileptic drugs. *Epilepsia* 1995;36:513–515.
83. Desai PB, Nallani SC, Sane RS, et al. Induction of cytochrome P450 3A4 in primary human hepatocytes and activation of the human pregnane X receptor by tamoxifen and 4-hydroxytamoxifen. *Drug Metab Dispos* 2002;30:608–612.
84. Dowsett M, Czuzik J, Howell A, et al. Pharmacokinetics of anastrozole and tamoxifen alone, and in combination, during adjuvant endocrine therapy for early breast cancer in postmenopausal women: a sub-protocol of the 'Arimidex and tamoxifen alone or in combination' (ATAC) trial. *Br J Cancer* 2001;85:317–324.
85. Pagani O, Gelber S, Price K, et al. Toremifene and tamoxifen are equally effective for early-stage breast cancer: first results of International Breast Cancer Study Group Trials 12-93 and 14-93. *Ann Oncol* 2004;15:1749–1759.
86. Hayes DF, Van Zyl JA, Hacking A, et al. Randomized comparison of tamoxifen and two separate doses of toremifene in postmenopausal patients with metastatic breast cancer. *J Clin Oncol* 1995;13:2556–2566.
87. Stenbygaard LE, Herrstedt J, Thomsen JF, et al. Toremifene and tamoxifen in advanced breast cancer—a double-blind cross-over trial. *Breast Cancer Res Treat* 1993;25:57–63.
88. Vogel CL, Shemano I, Schoenfelder J, et al. Multicenter phase II efficacy trial of toremifene in tamoxifen-refractory patients with advanced breast cancer. *J Clin Oncol* 1993;11:345–350.
89. Kangas L. Review of the pharmacological properties of toremifene. *J Steroid Biochem* 1990;36:191–195.
90. Berthou F, Dreano Y, Belloc C, et al. Involvement of cytochrome P450 3A enzyme family in the major metabolic pathways of toremifene in human liver microsomes. *Biochem Pharmacol* 1994;47:1883–1895.
91. Simberg NH, Murai JT, Siiteri PK. In vitro and in vivo binding of toremifene and its metabolites in rat uterus. *J Steroid Biochem* 1990;36:197–202.
92. Kohler PC, Hamm JT, Wiebe VJ, et al. Phase I study of the tolerance and pharmacokinetics of toremifene in patients with cancer. *Breast Cancer Res Treat* 1990;16 Suppl:S19–S26.
93. Tominaga T, Abe O, Izuo M. A phase I study of toremifene. *Breast Cancer Res Treat* 1990;16 (Suppl):27.
94. Wiebe VJ, Benz CC, Shemano I, et al. Pharmacokinetics of toremifene and its metabolites in patients with advanced breast cancer. *Cancer Chemother Pharmacol* 1990;25:247–251.
95. Anttila M, Laakso S, Nylanden P, et al. Pharmacokinetics of the novel antiestrogenic agent toremifene in subjects with altered liver and kidney function. *Clin Pharmacol Ther* 1995;57:628–635.
96. Hard CC, Iatropoulos MJ, Jordan K, et al. Major difference in the hepatocarcinogenicity and DNA adduct forming ability between toremifene and tamoxifen in female Crl:CD(BR) rats. *Cancer Res* 1993;53:4534–4541.
97. Montandon F, Williams GM. Comparison of DNA reactivity of the polyphenylethylene hormonal agents diethylstilbestrol, tamoxifen and toremifene in rat and hamster liver. *Arch Toxicol* 1994;68:272–275.
98. Vogel VG, Costantino JP, Wickerham DL, et al. Update of the National Surgical Adjuvant Breast and Bowel Project Study of Tamoxifen and Raloxifene (STAR) P-2 Trial: Preventing Breast Cancer. *Cancer Prev Res (Phila)* 2010;3:696–706.
99. Delmas PD, Balena R, Confravreux E, et al. Bisphosphonate risedronate prevents bone loss in women with artificial menopause due to chemotherapy of breast cancer: a double-blind, placebo-controlled study. *J Clin Oncol* 1997;15:955–962.
100. Draper MW, Flowers DE, Huster WJ, et al. A controlled trial of raloxifene (LY139481) HCl: impact on bone turnover and serum lipid profile in healthy postmenopausal women. *J Bone Miner Res* 1996;11:835–842.
101. Anzano MA, Peer CW, Smith JM, et al. Chemoprevention of mammary carcinogenesis in the rat: combined use of raloxifene and 9-cis-retinoic acid. *J Natl Cancer Inst* 1996;88:123–125.
102. Gottardis MM, Jordan VC. Antitumor actions of keoxifene and tamoxifen in the N-nitrosomethylurea-induced rat mammary carcinoma model. *Cancer Res* 1987;47:4020–4024.
103. Black LJ, Jones CD, Falcone JF. Antagonism of estrogen action with a new benzothioephene derived antiestrogen. *Life Sci* 1983;32:1031–1036.
104. Allerheiligen S, Geiser J, Knadler M. Raloxifene (RAL) pharmacokinetics and the associated endocrine effects in premenopausal women treated during the follicular, ovulatory, and luteal phases of the menstrual cycle. *Pharmaceut Res* 1996;13:S430.
105. Fogue ST, Rudy AC, Knadler MP. Raloxifene pharmacokinetics in healthy postmenopausal women. *Pharmaceut Res* 1996;13:S430.
106. Ni L, Allerheiligen S, Basson R. Pharmacokinetics of raloxifene in men and postmenopausal women volunteers. *Pharmaceut Res* 1996;13:S430.
107. Kemp DC, Fan PW, Stevens JC. Characterization of raloxifene glucuronidation in vitro: contribution of intestinal metabolism to presystemic clearance. *Drug Metab Dispos* 2002;30:694–700.
108. Coopman P, Garcia M, Brunner N, et al. Anti-proliferative and anti-estrogenic effects of ICI 164,384 and ICI 182,780 in 4-OH-tamoxifen-resistant human breast-cancer cells. *Int J Cancer* 1994;56:295–300.
109. Howell A, DeFriend DJ, Robertson JF, et al. Pharmacokinetics, pharmacological and anti-tumour effects of the specific anti-oestrogen ICI 182780 in women with advanced breast cancer. *Br J Cancer* 1996;74:300–308.
110. Howell A, Osborne CK, Morris C, et al. ICI 182,780 (Faslodex): development of a novel, "pure" antiestrogen. *Cancer* 2000;89:817–825.
111. Robertson JF, Odling-Smee W, Holcombe C, et al. Pharmacokinetics of a single dose of fulvestrant prolonged-release intramuscular injection in postmenopausal women awaiting surgery for primary breast cancer. *Clin Ther* 2003;25:1440–1452.
112. Piccart M, Parker LM, Pritchard KI. Oestrogen receptor downregulation: an opportunity for extending the window of endocrine therapy in advanced breast cancer. *Ann Oncol* 2003;14:1017–1025.

113. Wakeling AE, Bowler J. Steroidal pure antioestrogens. *J Endocrinol* 1987;112:R7–R10.
114. Wakeling AE, Dukes M, Bowler J. A potent specific pure antiestrogen with clinical potential. *Cancer Res* 1991;51:3867–3873.
115. Howell A, Robertson JF, Quaresma Albano J, et al. Fulvestrant, formerly ICI 182,780, is as effective as anastrozole in postmenopausal women with advanced breast cancer progressing after prior endocrine treatment. *J Clin Oncol* 2002;20:3396–3403.
116. Osborne CK, Pippen J, Jones SE, et al. Double-blind, randomized trial comparing the efficacy and tolerability of fulvestrant versus anastrozole in postmenopausal women with advanced breast cancer progressing on prior endocrine therapy: results of a North American trial. *J Clin Oncol* 2002;20:3386–3395.
117. Howell A, Robertson JF, Abram P, et al. Comparison of fulvestrant versus tamoxifen for the treatment of advanced breast cancer in postmenopausal women previously untreated with endocrine therapy: a multinational, double-blind, randomized trial. *J Clin Oncol* 2004;22:1605–1613.
118. Leo AD, Jerusalem G, Petruzelka L, et al. Final overall survival: fulvestrant 500 mg vs 250 mg in the randomized CONFIRM trial. *J Natl Cancer Inst* 2014;106:dj337.
119. McCormack P, Sapunar F. Pharmacokinetic profile of the fulvestrant loading dose regimen in postmenopausal women with hormone receptor-positive advanced breast cancer. *Clin Breast Cancer* 2008;8:347–351.
120. Scheingart DE, Cash R, Conn JW. Amino-glutethimide and metastatic adrenal cancer. Maintained reversal (six months) of Cushing's syndrome. *JAMA* 1996;198:1007–1010.
121. Ma CX, Adjei AA, Salavaggione OE, et al. Human aromatase: gene resequencing and functional genomics. *Cancer Res* 2005;65:11071–11082.
122. Colomer R, Monzo M, Tusquets I, et al. A single-nucleotide polymorphism in the aromatase gene is associated with the efficacy of the aromatase inhibitor letrozole in advanced breast carcinoma. *Clin Cancer Res* 2008;14:811–816.
123. Wang L, Ellsworth KA, Moon I, et al. Functional genetic polymorphisms in the aromatase gene CYP19 vary the response of breast cancer patients to neoadjuvant therapy with aromatase inhibitors. *Cancer Res* 2010;70:319–328.
124. Goss PE, Ingle JN, Martino S, et al. A randomized trial of letrozole in postmenopausal women after five years of tamoxifen therapy for early-stage breast cancer. *N Engl J Med* 2003;349:1793–1802.
125. Mouridsen H, Gershonovich M, Sun Y, et al. Phase III study of letrozole versus tamoxifen as first-line therapy of advanced breast cancer in postmenopausal women: analysis of survival and update of efficacy from the International Letrozole Breast Cancer Group. *J Clin Oncol* 2003;21:2101–2109.
126. Howell A, Cuzick J, Baum M, et al. Results of the ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial after completion of 5 years' adjuvant treatment for breast cancer. *Lancet* 2005;365:60–62.
127. Thurlimann B, Keshaviah A, Coates AS, et al. A comparison of letrozole and tamoxifen in postmenopausal women with early breast cancer. *N Engl J Med* 2005;353:2747–2757.
128. Jakesz R, Jonat W, Gnani M, et al. Switching of postmenopausal women with endocrine-responsive early breast cancer to anastrozole after 2 years' adjuvant tamoxifen: combined results of ABCSG trial 8 and ARNO 95 trial. *Lancet* 2005;366:455–462.
129. Cuzick J, Sestak I, Forbes JF, et al. Anastrozole for prevention of breast cancer in high-risk postmenopausal women (IBIS-II): an international, double-blind, randomised placebo-controlled trial. *Lancet* 2014;383:1041–1048.
130. Baum M, Budzar AU, Cuzick J, et al. Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early breast cancer: first results of the ATAC randomised trial. *Lancet* 2002;359:2131–2139.
131. Amir E, Seruga B, Nira S, et al. Toxicity of adjuvant endocrine therapy in postmenopausal breast cancer patients: a systematic review and meta-analysis. *J Natl Cancer Inst* 2011;103:1299–1309.
132. Plourde PV, Dyroff M, Dukes M. Arimidex: a potent and selective fourth-generation aromatase inhibitor. *Breast Cancer Res Treat* 1994;30:103–111.
133. Bisagni G, Cocconi G, Scaglione F, et al. Letrozole, a new oral non-steroidal aromatase inhibitor in treating postmenopausal patients with advanced breast cancer. A pilot study. *Ann Oncol* 1996;7:99–102.
134. Budzar AU. Pharmacology and pharmacokinetics of the newer generation aromatase inhibitors. *Clin Cancer Res* 2003;9:468S–472S.
135. Dewar JA, Nabholz JM, Bonnetterre J, et al. The effect of anastrozole (Arimidex) on serum lipids: data from a randomized comparison of anastrozole (AN) versus tamoxifen (TAM) in postmenopausal (PM) women with advanced breast cancer (ABC). *Breast Cancer Res Treat* 2000;64:51.
136. Elisaf MS, Bairaktari ET, Nicolaidis C, et al. Effect of letrozole on the lipid profile in postmenopausal women with breast cancer. *Eur J Cancer* 2001;37:1510–1513.
137. Bhatnagar AS, Hausler A, Schieweck K. Inhibition of aromatase in vitro and in vivo by aromatase inhibitors. *J Enzyme Inhib* 1990;4:179–186.
138. Bhatnagar AS, Hausler A, Schieweck K, et al. Highly selective inhibition of estrogen biosynthesis by CGS 20267, a new non-steroidal aromatase inhibitor. *J Steroid Biochem Mol Biol* 1990;37:1021–1027.
139. Demers LM. Effects of Fadrozole (CGS 16949A) and Letrozole (CGS 20267) on the inhibition of aromatase activity in breast cancer patients. *Breast Cancer Res Treat* 1994;30:95–102.
140. Lipton A, Demers LM, Harvey HA, et al. Letrozole (CGS 20267). A phase I study of a new potent oral aromatase inhibitor of breast cancer. *Cancer* 1995;75:2132–2138.
141. Iveson TJ, Smith IE, Ahern J, et al. Phase I study of the oral nonsteroidal aromatase inhibitor CGS 20267 in postmenopausal patients with advanced breast cancer. *Cancer Res* 1993;53:266–270.
142. Trunet PF, Muller PH, Bhatnagar A. Phase I study in healthy male volunteers with the non-steroidal aromatase inhibitor GCS 20267. *Eur J Cancer* 1990;26:173.
143. Dukes M, Edwards PN, Large M, et al. The preclinical pharmacology of "Arimidex" (anastrozole; ZD1033)—a potent, selective aromatase inhibitor. *J Steroid Biochem Mol Biol* 1996;58:439–445.
144. Yates RA, Dowsett M, Fisher GV, et al. Arimidex (ZD1033): a selective, potent inhibitor of aromatase in postmenopausal female volunteers. *Br J Cancer* 1996;73:543–548.
145. Lønning PE, Geisler J, Dowsett M. Pharmacological and clinical profile of anastrozole. *Breast Cancer Res Treat* 1998;49:S53–S57.
146. Geisler J, King N, Dowsett M, et al. Influence of anastrozole (Arimidex), a selective, non-steroidal aromatase inhibitor, on in vivo aromatization and plasma oestrogen levels in postmenopausal women with breast cancer. *Br J Cancer* 1996;74:1286–1291.
147. Ingle JN, Budzar AU, Schaid DJ, et al. Variation in anastrozole metabolism and pharmacodynamics in women with early breast cancer. *Cancer Res* 2010;70:3278–3286.
148. Kaufmann M, Bajetta E, Dirix LY, et al. Exemestane is superior to megestrol acetate after tamoxifen failure in postmenopausal women with advanced breast cancer: results of a phase III randomized double-blind trial. The Exemestane Study Group. *J Clin Oncol* 2000;18:1399–1411.
149. Goss PE, Ingle JN, Pritchard KI, et al. Exemestane versus anastrozole in postmenopausal women with early breast cancer: NCIC CTG MA.27—a randomized controlled phase III trial. *J Clin Oncol* 2013;31:1398–1404.
150. Goss PE, Ingle JN, Ales-Martinez JE, et al. Exemestane for breast-cancer prevention in postmenopausal women. *N Engl J Med* 2011;364:2381–2391.
151. Goss PE, Grynypas M, Qi S, et al. The effects of exemestane on bone and lipids in the ovariectomized rat. *Breast Cancer Res Treat* 2001;69:224.
152. Evans TR, Di Salle E, Ornat G, et al. Phase I and endocrine study of exemestane (FCE 24304), a new aromatase inhibitor, in postmenopausal women. *Cancer Res* 1992;52:5933–5939.
153. Bajetta E, Zilembo N, Noverasco C, et al. The minimal effective exemestane dose for endocrine activity in advanced breast cancer. *Eur J Cancer* 1997;33:587–591.
154. Michaud LB, Budzar AU. Risks and benefits of aromatase inhibitors in postmenopausal breast cancer. *Drug Saf* 1999;21:297–309.
155. Coombes RC, Hall E, Gibson LJ, et al. A randomized trial of exemestane after two to three years of tamoxifen therapy in postmenopausal women with primary breast cancer. *N Engl J Med* 2004;350:1081–1092.
156. Demers LM, Lipton A, Harvey HA, et al. The efficacy of CGS 20267 in suppressing estrogen biosynthesis in patients with advanced stage breast cancer. *J Steroid Biochem Mol Biol* 1993;44:687–691.
157. Spinelli R, Jannuzzo MG, Poggessi I, et al. Pharmacokinetics (PK) of Aromasin (Exemestane, EXE) after single and repeated doses in healthy postmenopausal volunteers (HPV). *Eur J Cancer* 1999;35:S295.
158. Budzar A, Howell A. Advances in aromatase inhibition: clinical efficacy and tolerability in the treatment of breast cancer. *Clin Cancer Res* 2001;7:2620–2635.
159. Johannessen DC, Engan T, Di Salle E, et al. Endocrine and clinical effects of exemestane (PNU 155971), a novel steroidal aromatase inhibitor, in postmenopausal breast cancer patients: a phase I study. *Clin Cancer Res* 1997;3:1101–1108.
160. Jones S, Vogel C, Arkhipov A, et al. Multicenter, phase II trial of exemestane as third-line hormonal therapy of postmenopausal women with metastatic breast cancer. Aromasin Study Group. *J Clin Oncol* 1999;17:3418–3425.
161. Ahmann FR, Citrin DL, deHaan HA, et al. Zoladex: a sustained-release, monthly luteinizing hormone-releasing hormone analogue for the treatment of advanced prostate cancer. *J Clin Oncol* 1987;5:912–917.
162. Corbin A. From contraception to cancer: a review of the therapeutic applications of LHRH analogues as antitumor agents. *Yale J Biol Med* 1982;55:27–47.
163. Kaufmann M, Jonat W, Blamey R, et al. Survival analyses from the ZEBRA study. Goserelin (Zoladex) versus CMF in premenopausal women with node-positive breast cancer. *Eur J Cancer* 2003;39:1711–1717.
164. Harvey HA, Lipton A, Max DT, et al. Medical castration produced by the GnRH analogue leuprolide to treat metastatic breast cancer. *J Clin Oncol* 1985;3:1068–1072.
165. Abrahamson PA. Potential benefits of intermittent androgen suppression therapy in the treatment of prostate cancer: a systematic review of the literature. *Eur Urol* 2010;57:49–59.
166. Hussain M, Tangen CM, Berry DL, et al. Intermittent versus continuous androgen deprivation in prostate cancer. *N Engl J Med* 2013;368:1314–1325.
167. Brogden RN, Faulds D. Goserelin. A review of its pharmacodynamic and pharmacokinetic properties and therapeutic efficacy in prostate cancer. *Drugs Aging* 1995;6:324–343.
168. Vogelzang NJ, Chodak GW, Soloway MS, et al. Goserelin versus orchiectomy in the treatment of advanced prostate cancer: final results of a randomized trial. Zoladex Prostate Study Group. *Urology* 1995;46:220–226.

169. Plosker GL, Brogden RN. Leuprorelin. A review of its pharmacology and therapeutic use in prostatic cancer, endometriosis and other sex hormone-related disorders. *Drugs* 1994;48:930-967.
170. Nillius SJ. *The Therapeutic Uses of Gonadotropin-Releasing Hormone and Its Analogues*. London: Butterworth; 1981.
171. Klijn JC, DeJong FH, Blankenstein MA. Anti-tumor and endocrine effects of chronic LHRH agonist treatment (buserelin) with or without tamoxifen in premenopausal metastatic breast cancer. *Breast Cancer Res Treat* 1984;4:209.
172. Clayton RN, Bailey LC, Cottam J, et al. A radioimmunoassay for GnRH agonist analogue in serum of patients with prostate cancer treated with D-Ser (tBu)<sub>6</sub> AZA Gly10 GnRH. *Clin Endocrinol (Oxf)* 1985;22:453-462.
173. Chrisp P, Goa KL. Goserelin. A review of its pharmacodynamic and pharmacokinetic properties, and clinical use in sex hormone-related conditions. *Drugs* 1991;41:254-288.
174. Samant MP, Hong DJ, Croston G, et al. Novel gonadotropin-releasing hormone antagonists with substitutions at position 5. *Biopolymers* 2005;80:386-391.
175. Van Poppel H, Tombal B, de la Rosette JJ, et al. Degarelix: a novel gonadotropin-releasing hormone (GnRH) receptor blocker—results from a 1-yr, multicentre, randomised, phase 2 dosage-finding study in the treatment of prostate cancer. *Eur Urol* 2008;54:805-813.
176. Klotz L, Boccon-Gibod L, Shore ND, et al. The efficacy and safety of degarelix: a 12-month, comparative, randomized, open-label, parallel-group phase III study in patients with prostate cancer. *BJU Int* 2008;102:1531-1538.
177. Steinberg M. Degarelix: a gonadotropin-releasing hormone antagonist for the management of prostate cancer. *Clin Ther* 2009;31:2312-2331.
178. Brogden RN, Clissold SP. Flutamide. A preliminary review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in advanced prostatic cancer. *Drugs* 1989;38:185-203.
179. Wysowski DK, Freiman JP, Tourtelot JB, et al. Fatal and nonfatal hepatotoxicity associated with flutamide. *Ann Intern Med* 1993;118:860-864.
180. Brogden RN, Chrisp P. Flutamide. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in advanced prostatic cancer. *Drugs Aging* 1991;1:104-115.
181. Radwanski E, Perentesis G, Szymchowicz S, et al. Single and multiple dose pharmacokinetic evaluation of flutamide in normal geriatric volunteers. *J Clin Pharmacol* 1989;29:554-558.
182. Schellhammer PF, Sharifi R, Block NL, et al. A controlled trial of bicalutamide versus flutamide, each in combination with luteinizing hormone-releasing hormone analogue therapy, in patients with advanced prostate carcinoma. Analysis of time to progression. CASODEX Combination Study Group. *Cancer* 1996;78:2164-2169.
183. Furr BJ. Casodex (ICI 176,334)—a new, pure, peripherally-selective anti-androgen: preclinical studies. *Horm Res* 1989;32:69.
184. Furr BJ. Casodex: preclinical studies. *Eur Urol* 1990;18:2.
185. Kennealey GT, Furr BJ. Use of the nonsteroidal anti-androgen Casodex in advanced prostatic carcinoma. *Urol Clin North Am* 1991;18:99-110.
186. Attard C, Reid AH, A'Hern R, et al. Selective inhibition of CYP17 with abiraterone acetate is highly active in the treatment of castration-resistant prostate cancer. *J Clin Oncol* 2009;27:3742-3748.
187. Tran C, Ouk S, Clegg NJ, et al. Development of a second-generation antiandrogen for treatment of advanced prostate cancer. *Science* 2009;324:787-790.
188. Scher HI, Fizazi K, Saad F, et al. Increased survival with enzalutamide in prostate cancer after chemotherapy. *N Engl J Med* 2012;367:1187-1197.
189. Zhu H, Garcia JA. Targeting the adrenal gland in castration-resistant prostate cancer: a case for orteronel, a selective CYP-17 17,20-lyase inhibitor. *Curr Oncol Rep* 2013;15:105-112.
190. Kennedy BJ. Hormonal therapies in breast cancer. *Semin Oncol* 1974;1:119-130.
191. Colburn WA. Radioimmunoassay for fluoxymesterone (Halotestin). *Steroids* 1975;25:43-52.
192. Kammerer RC, Merdink JL, Jagels M, et al. Testing for fluoxymesterone (Halotestin) administration to man: identification of urinary metabolites by gas chromatography-mass spectrometry. *J Steroid Biochem* 1990;36:659-666.
193. Ingle JN, Ahmann DL, Green SJ, et al. Randomized clinical trial of diethylstilbestrol versus tamoxifen in postmenopausal women with advanced breast cancer. *N Engl J Med* 1981;304:16-21.
194. Stewart HJ, Forrester AP, Gunn JM, et al. The tamoxifen trial - a double-blind comparison with stilboestrol in postmenopausal women with advanced breast cancer. *Eur J Cancer* 1980;Suppl 1:83-88.
195. Byar DP. Proceedings: The Veterans Administration Cooperative Urological Research Group's studies of cancer of the prostate. *Cancer* 1973;32:1126-1130.
196. Loose-Mitchell DS, Stancel GM. *Estrogens and Progestins*. 10 ed. New York: McGraw-Hill; 2001.
197. Bonomi P, Pessis D, Bunting N, et al. Megestrol acetate used as primary hormonal therapy in stage D prostatic cancer. *Semin Oncol* 1985;12:36-39.
198. Bruera E, Macmillan K, Kuehn N, et al. A controlled trial of megestrol acetate on appetite, caloric intake, nutritional status, and other symptoms in patients with advanced cancer. *Cancer* 1990;66:1279-1282.
199. Feliu J, Gonzalez-Baron M, Berrocal A, et al. Usefulness of megestrol acetate in cancer cachexia and anorexia. A placebo-controlled study. *Am J Clin Oncol* 1992;15:436-440.
200. Loprinzi CL, Ellison NM, Schaid DJ, et al. Controlled trial of megestrol acetate for the treatment of cancer anorexia and cachexia. *J Natl Cancer Inst* 1990;82:1127-1132.
201. Tchekmedyan NS, Hickman M, Siau J, et al. Megestrol acetate in cancer anorexia and weight loss. *Cancer* 1992;69:1268-1274.
202. Loprinzi CL, Michalak JC, Schaid DJ, et al. Phase III evaluation of four doses of megestrol acetate as therapy for patients with cancer anorexia and/or cachexia. *J Clin Oncol* 1993;11:762-767.
203. Loprinzi CL, Jensen MD, Jiang NS, et al. Effect of megestrol acetate on the human pituitary-adrenal axis. *Mayo Clin Proc* 1992;67:1160-1162.
204. Leinung MC, Liporace R, Miller CH. Induction of adrenal suppression by megestrol acetate in patients with AIDS. *Ann Intern Med* 1995;122:843-845.
205. Rowland KM Jr, Loprinzi CL, Shaw EG, et al. Randomized double-blind placebo-controlled trial of cisplatin and etoposide plus megestrol acetate/placebo in extensive-stage small-cell lung cancer: a North Central Cancer Treatment Group study. *J Clin Oncol* 1996;14:135-141.
206. Loprinzi CL, Johnson PA, Jensen M. Megestrol acetate for anorexia and cachexia. *Oncology* 1992;49:46-49.
207. Von Roenn JH, Armstrong D, Kotler DP, et al. Megestrol acetate in patients with AIDS-related cachexia. *Ann Intern Med* 1994;121:393-399.
208. Alexieva-Figusch J, Blankenstein MA, Hop WC, et al. Treatment of metastatic breast cancer patients with different dosages of megestrol acetate; dose relations, metabolic and endocrine effects. *Eur J Cancer Clin Oncol* 1984;20:33-40.
209. Tseng L, Gurpide E. Effects of progestins on estradiol receptor levels in human endometrium. *J Clin Endocrinol Metab* 1975;41:402-404.
210. Gurpide E, Tseng L, Gusberg SB. Estrogen metabolism in normal and neoplastic endometrium. *Am J Obstet Gynecol* 1977;129:809-816.
211. Gordon GG, Altman K, Southren AL, et al. Human hepatic testosterone A-ring reductase activity: effect of medroxyprogesterone acetate. *J Clin Endocrinol Metab* 1971;32:457-461.
212. Allegra JC, Kiefer SM. Mechanisms of action of progestational agents. *Semin Oncol* 1985;12:3-5.
213. Ewing TM, Murphy LJ, Ng ML, et al. Regulation of epidermal growth factor receptor by progestins and glucocorticoids in human breast cancer cell lines. *Int J Cancer* 1989;44:744-752.
214. Adlercreutz H, Eriksen PB, Christensen MS. Plasma concentration of megestrol acetate and medroxyprogesterone acetate after single oral administration to healthy subjects. *J Pharm Biomed Anal* 1983;1:153.
215. Martin F, Adlercreutz H, eds. *Aspects of Megestrol Acetate and Medroxyprogesterone Acetate Metabolism*. New York: Raven Press; 1977.
216. Gaver RC, Pittman KA, Reilly CM, et al. Bioequivalence evaluation of new megestrol acetate formulations in humans. *Semin Oncol* 1985;12:17-19.
217. Fotherby K, Kamyab S, Littleton P. Metabolism of synthetic progestational compounds in humans. *J Reprod Fertil* 1968;5:51-61.
218. Fukushima DK, Levin J, Liang JS, et al. Isolation and partial synthesis of a new metabolite of medroxyprogesterone acetate. *Steroids* 1979;34:57-72.
219. Utaaker E, Lundgren S, Kvinnsland S, et al. Pharmacokinetics and metabolism of medroxyprogesterone acetate in patients with advanced breast cancer. *J Steroid Biochem* 1988;31:437-441.
220. Sturm G, Haberlein H, Bauer T, et al. Mass spectrometric and high-performance liquid chromatographic studies of medroxyprogesterone acetate metabolites in human plasma. *J Chromatogr* 1991;562:351-362.
221. Pannuti F, Camaggi CM, Strocchi E, eds. *Medroxyprogesterone Acetate Pharmacokinetics*. New York: Raven Press; 1984.
222. Lundgren S, Lonning PE, Aakvaag A, et al. Influence of aminoglutethimide on the metabolism of medroxyprogesterone acetate and megestrol acetate in postmenopausal patients with advanced breast cancer. *Cancer Chemother Pharmacol* 1990;27:101-105.
223. Lundgren S, Kvinnsland S, Utaaker E, et al. Effect of oral high-dose progestins on the disposition of antipyrine, digitoxin, and warfarin in patients with advanced breast cancer. *Cancer Chemother Pharmacol* 1986;18:270-275.
224. Cascinu S, Fedeli A, Fedeli SL, et al. Control of chemotherapy-induced diarrhoea with octreotide in patients receiving 5-fluorouracil. *Eur J Cancer* 1992;28:482-483.
225. Cascinu S, Fedeli A, Fedeli SL, et al. Octreotide versus loperamide in the treatment of fluorouracil-induced diarrhea: a randomized trial. *J Clin Oncol* 1993;11:148-151.
226. Gebbia V, Carreca I, Testa A, et al. Subcutaneous octreotide versus oral loperamide in the treatment of diarrhea following chemotherapy. *Anticancer Drugs* 1993;4:443-445.
227. Harris AG. Somatostatin and somatostatin analogues: pharmacokinetics and pharmacodynamic effects. *Gut* 1994;35:S1-S4.
228. Chanson P, Timsit J, Harris AG. Clinical pharmacokinetics of octreotide. Therapeutic applications in patients with pituitary tumours. *Clin Pharmacokinet* 1993;25:375-391.
229. Marbach P, Briner U, Lemaire M. From somatostatin to Sandostatin: pharmacodynamics and pharmacokinetics. *Digestion* 1993;54:9-13.
230. Rubin J, Ajani J, Schirmer W, et al. Octreotide acetate long-acting formulation versus open-label subcutaneous octreotide acetate in malignant carcinoid syndrome. *J Clin Oncol* 1999;17:600-606.